Article

Impact of Age, Phenotype and Cardio-Renal Function on Plasma C-Type and B-Type Natriuretic Peptide Forms in an Adult Population.

Department of Medicine, University of Otago, Christchurch, New Zealand.
Clinical Endocrinology (Impact Factor: 3.35). 09/2012; 78(5). DOI: 10.1111/cen.12035
Source: PubMed

ABSTRACT CONTEXT: In contrast to the cardiac hormones, Atrial Natriuretic Peptide (ANP) and B-type Natriuretic Peptide (BNP), variations in plasma concentrations of C-type Natriuretic Peptide (CNP) in healthy adults are ill-defined, limiting their clinical application. OBJECTIVE: Our objective was to define the effect of age, phenotype (gender, height, BMI), and cardiac and renal function on plasma CNP peptides in an adults population without renal or cardiovascular disease. DESIGN AND SETTING: This was a prospective cross sectional observational study of adult volunteers, aged 21-80yr, randomly selected from the electoral roll. SUBJECTS AND METHODS: Plasma CNP and its associated aminoterminal propeptide (NTproCNP) were measured in 258 subjects and related to age, gender, height and plasma creatinine. Sub group analyses seeking associations with cardiac function (plasma BNP and NTproBNP) and bone turnover (bALP) were also determined. RESULTS: Plasma concentrations of CNP peptides in men continued to decline from adolescent values to reach a nadir in the 5(th) decade after which values increased. Similar but less marked changes occurred in women. In both sexes, NTproCNP was inversely and independently correlated with height. In contrast to BNP peptides, NTproCNP was higher in men, significantly related to creatinine and positively related to bALP. CONCLUSIONS: Gender and age specific changes affect CNP peptides in adults. Inverse associations of NTproCNP with adult height, positive correlation with creatinine - and in contrast to CNP - no association with BNP are further unique findings distinguishing NTproCNP which need to be considered in future studies. © 2012 Blackwell Publishing Ltd.

0 Followers
 · 
59 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine changes in plasma C-type natriuretic peptide (CNP), a paracrine product of the vascular endothelium, in pregnancies with vascular disorders, and relate these to time of presentation and severity. Retrospective nested cases and controls. Community study, Auckland New Zealand. Screening for Pregnancy Endpoints (SCOPE) data and bio-bank of maternal plasma. Maternal plasma amino terminal proCNP (NTproCNP) was measured by radioimmunoassay in early (14-16 weeks of gestation, and again at 19-21 weeks of gestation) and late (34-36 weeks of gestation) pregnancy in three groups of women (20 per group): pre-eclampsia (pre-eclampsia); gestational hypertension (GHT) with small for gestational age (SGA); and uncomplicated pregnancy. Change in NTproCNP and associations with concurrent blood pressure, time of case presentation, severity, and infant birthweight. Plasma NTproCNP in early pregnancy in women with vascular disorders did not differ from those found in controls. In late pregnancy, levels in pre-eclampsia (28.8 ± 2.3 pM) and in GHT with SGA (28.6 ± 4.8 pM) were significantly increased (P = 0.01 and 0.027, respectively) compared with controls (21.3 ± 1 pM). In pre-eclampsia, levels were significantly higher (P < 0.03) at 14-16 weeks of gestation in women diagnosed prior to 34 weeks of gestation. Combining all three groups, associations of NTproCNP with concurrent diastolic and mean arterial pressure were found at 34-36 weeks of gestation (r = 0.46). No significant associations were identified with birthweight. CNP secretion during gestation is responsive to vascular stress. Plasma NTproCNP measurements may have clinical application in late pregnancy in defining the different phenotypes associated with pre-eclampsia. © 2015 Royal College of Obstetricians and Gynaecologists.
    BJOG An International Journal of Obstetrics & Gynaecology 04/2015; DOI:10.1111/1471-0528.13397 · 3.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: C-type natriuretic peptide (CNP) is a paracrine growth factor with high abundance in CNS tissues and cerebrospinal fluid (CSF). Consistent with findings of CNP transcripts in the cerebral microvasculature and hypothalamus, CNP increases the permeability of the blood-brain barrier and reduces food intake when administered intracerebroventricularly in rodents. Whether high concentrations of CNP in plasma can affect CSF levels is unknown. Accordingly we have studied changes (days 4, 87 and 116) in concurrent plasma and CSF concentrations of CNP peptides in pregnant sheep-a physiologically unique setting in which plasma CNP is elevated for prolonged periods. Preliminary studies in non pregnant sheep showed stable CNP levels in CSF during repetitive sampling. Compared with values in non pregnant controls, plasma concentrations of CNP peptides were markedly raised (30-fold) at days 87 and 116 in pregnant sheep, yet CSF levels in the two groups did not differ. CNP peptides in CSF decreased from day 4 to day 87 in pregnant sheep, possibly reflecting an adaptive response of the cerebral vasculature to increased hemodynamic load. We conclude that sustained high concentrations of CNP-far exceeding levels encountered in human pathophysiology-fail to affect CNP peptide levels in CSF. Copyright © 2015. Published by Elsevier Inc.
    Peptides 04/2015; 69. DOI:10.1016/j.peptides.2015.04.016 · 2.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: C-type natriuretic peptide (CNP) is an endothelium-derived peptide that is released as a protective mechanism in response cardiovascular injury or disease. However, no studies have investigated circulating CNP, identifying clinical factors that may influence CNP and its relationship to cardiovascular disease in the general population. We studied 1841 randomly selected subjects from Olmsted County, MN (mean age, 63±11 years; 48% men). Plasma CNP was measured by a well-established radioimmunoassay and echocardiography, clinical characterization, and detailed medical record review were performed. We report that CNP circulates at various concentrations (median, 13 pg/mL), was unaffected by sex, was weakly associated by age, and that highest quartile of CNP identified a high-risk phenotype. Subjects with CNP in the highest quartile were associated with increased risk of myocardial infarction (multivariable-adjusted hazard ratio, 1.51; 95% confidence interval, 1.09-2.09; P=0.01) but not heart failure, cerebrovascular accidents, or death during a follow-up of 12 years. Addition of the highest quartile of CNP to clinical variables led to a modest increase in the integrated discrimination improvement for risk of myocardial infarction. In a large community-based cohort, elevated circulating CNP identified a high-risk phenotype that included cardiovascular comorbidities and left ventricular dysfunction, and provided evidence that highest concentrations of CNP potentially has prognostic value in predicting future risk of myocardial infarction. Together, these data from the general population highlight the potential value of CNP and support the need for additional studies to evaluate whether mechanisms regulating CNP could improve outcomes. © 2015 American Heart Association, Inc.
    Hypertension 04/2015; DOI:10.1161/HYPERTENSIONAHA.115.05366 · 7.63 Impact Factor